Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 118

1.

Treatment of chronic kidney disease.

Turner JM, Bauer C, Abramowitz MK, Melamed ML, Hostetter TH.

Kidney Int. 2012 Feb;81(4):351-62. doi: 10.1038/ki.2011.380. Epub 2011 Dec 14. Review.

2.

Arterial hypertension and proteinuria in pediatric chronic kidney disease.

Simonetti GD, Bucher BS, Tschumi S, Lava SA, Bianchetti MG.

Minerva Pediatr. 2012 Apr;64(2):171-82. Review.

PMID:
22495191
3.

Renoprotective effect of renin-angiotensin-aldosterone system blockade in patients with predialysis advanced chronic kidney disease, hypertension, and anemia.

Hsu TW, Liu JS, Hung SC, Kuo KL, Chang YK, Chen YC, Hsu CC, Tarng DC.

JAMA Intern Med. 2014 Mar;174(3):347-54. doi: 10.1001/jamainternmed.2013.12700.

PMID:
24343093
4.

Hypertension Management in Transition: From CKD to ESRD.

Valika A, Peixoto AJ.

Adv Chronic Kidney Dis. 2016 Jul;23(4):255-61. doi: 10.1053/j.ackd.2016.02.002. Review.

PMID:
27324679
5.

Calcium channel blockers in the prevention of end stage renal disease: a review.

Derwa A, Peeters P, Vanholder R.

Acta Clin Belg. 2004 Jan-Feb;59(1):44-56. Review.

PMID:
15065696
6.

Addition of vitamin D reverses the decline in GFR following treatment with ACE inhibitors/angiotensin receptor blockers in patients with chronic kidney disease.

Soares AE, Maes M, Godeny P, Matsumoto AK, Barbosa DS, da Silva TAF, Souza FHMO, Delfino VDA.

Life Sci. 2017 Dec 15;191:175-179. doi: 10.1016/j.lfs.2017.10.028.

PMID:
29079468
7.

[Can progression to terminal renal insufficiency be avoided in diabetic nephropathy?].

Luño J, Valderrábano F.

An Med Interna. 1998 Nov;15(11):567-71. Review. Spanish. No abstract available.

PMID:
9882851
8.

[Risk and prevention of diabetic nephropathy].

Ravera M, Re M, Deferrari G.

G Ital Nefrol. 2007 Sep-Oct;24 Suppl 38:13-9. Italian.

PMID:
17922442
9.
11.

The Remission Clinic approach to halt the progression of kidney disease.

Remission Clinic Task Force; Clinical Research Center "Aldo e Cele Daccò".

J Nephrol. 2011 May-Jun;24(3):274-81. doi: 10.5301/JN.2011.7763.

PMID:
21534237
12.

[Oral inhibitors of renin and their potential use as therapeutic agents in treating hypertension].

Abassi Z, Armaly Z, Nakhoul F, Hoffman A.

Harefuah. 2008 Jun;147(6):536-42, 573. Review. Hebrew.

PMID:
18693632
13.

The renoprotective effects of RAS inhibition: focus on prevention and treatment of chronic kidney disease.

Weir MR.

Postgrad Med. 2009 Jan;121(1):96-103. doi: 10.3810/pgm.2009.01.1958.

PMID:
19179817
14.

Renal protection with angiotensin receptor blockers: where do we stand.

Schmieder RE, Ruilope LM, Barnett AH.

J Nephrol. 2011 Sep-Oct;24(5):569-80. doi: 10.5301/JN.2011.6445. Review.

PMID:
21404225
15.

Recommendations for the management of special populations: renal disease in diabetes.

Raij L.

Am J Hypertens. 2003 Nov;16(11 Pt 2):46S-49S. Review.

PMID:
14625161
16.

High risk of ESRD in type 1 diabetes: new strategies are needed to retard progressive renal function decline.

Krolewski AS, Bonventre JV.

Semin Nephrol. 2012 Sep;32(5):407-14. doi: 10.1016/j.semnephrol.2012.07.002.

17.
20.

Angiotensin converting enzyme inhibitors and angiotensin receptor blockers in the treatment of hypertension: should they be used together?

Verdecchia P, Angeli F, Mazzotta G, Ambrosio G, Reboldi G.

Curr Vasc Pharmacol. 2010 Nov;8(6):742-6.

PMID:
20626343

Supplemental Content

Support Center